Literature DB >> 15068321

Sex differences in survival in non-small cell lung cancer patients 1974-1998.

Rhonda Moore1, Dorota Doherty, Robert Chamberlain, Fadlo Khuri.   

Abstract

This study comprised a total of 7,553 patients with non-small cell lung cancer (2,660 women and 4,893 men) treated at a comprehensive cancer centre between 1974 and 1998. Significant differences in tumour histology were associated with gender (p < 0.001); adenocarcinoma was the most common diagnosis in both men (50.0%) and women (41.7%); squamous cell carcinoma was the second most prevalent diagnosis (21% and 31% in women and men, respectively); and bronchioalveolar tumours were more prevalent in men (3% compared with 7% in women). Frequency distributions with local, regional or distant disease at registration were similar between men and women (p = 0.906). In a multivariable Cox regression analysis the indications were that gender is an important risk factor for survival. Adjusting for age, stage, treatment received and ability to pay for care, a statistically significant interaction between gender and tumour histology (p = 0.043) was found, where, in relation to female sex and histologies other than squamous carcinoma, women who presented with squamous carcinoma had an increased risk of death (HR = 1.09, 95% CI 1.02-1.18) while men had an increased risk of death for all histologies (HR = 1.29, 95% CI 1.21-1.40, and HR = 1.15, 95% CI 1.07-1.24 for squamous and other histologies, respectively). This study confirms previous reports of strong gender-dependent differences in survival in patients with non-small cell lung cancer, including a histology-specific effect in women.

Entities:  

Mesh:

Year:  2004        PMID: 15068321

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

1.  Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.

Authors:  Julie R Brahmer; Suzanne E Dahlberg; Robert J Gray; Joan H Schiller; Michael C Perry; Alan Sandler; David H Johnson
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

Review 2.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

3.  Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer.

Authors:  Joanne L Yu; Christine Simmons; J Charles Victor; Dolly Han; Sophie Hogeveen; Natasha Leighl; Sunil Verma
Journal:  Oncologist       Date:  2011-08-11

Review 4.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

5.  Age and gender differences in medicare expenditures and service utilization at the end of life for lung cancer decedents.

Authors:  Lisa R Shugarman; Chloe E Bird; Cynthia R Schuster; Joanne Lynn
Journal:  Womens Health Issues       Date:  2008 May-Jun

6.  Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study.

Authors:  M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2018-10-19       Impact factor: 3.405

7.  Reduced coenzyme Q(10) in female smokers and its association with lipid profile in a young healthy adult population.

Authors:  Maha M Al-Bazi; Mohamed F Elshal; Samir M Khoja
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

8.  Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.

Authors:  Go Saito; Takahiro Ebata; Tsukasa Ishiwata; Shunichiro Iwasawa; Ichiro Yoshino; Yuichi Takiguchi; Koichiro Tatsumi
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.359

9.  Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer.

Authors:  Takeshi Hanagiri; Kenji Sugio; Hidetaka Uramoto; Tetsuya So; Yoshinobu Ichiki; Masakazu Sugaya; Kenji Ono; Manabu Yasuda; Tadahiro Nozoe; Kosei Yasumoto
Journal:  Surg Today       Date:  2007-06-26       Impact factor: 2.540

10.  Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis.

Authors:  Oscar Arrieta; David Saavedra-Perez; Roberto Kuri; Alejandro Aviles-Salas; Luis Martinez; Daniel Mendoza-Posada; Patricia Castillo; Alma Astorga; Enrique Guzman; Jaime De la Garza
Journal:  BMC Cancer       Date:  2009-04-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.